fbpx

Amniotics presents positive preclinical data on stem cell treatment

Facebook
Twitter
LinkedIn
Claus Thestrup

Claus Thestrup

CEO, HCA Capital Sweden

Amniotics presents positive preclinical data on stem cell treatment for chemotherapy-induced peripheral neuropathy at ICRBE 2022.

Amniotics has announced that an abstract with new promising preclinical data on the treatment of chemotherapy-induced peripheral neuropathy (CIPN) with mesenchymal stem cells (MSC) has been accepted for a poster presentation at the 16th International Conference on Regenerative Biology and Engineering (ICRBE) taking place on July 28-29 in Zurich, Switzerland. The presentation includes preclinical results showing that treatment with MSC selected for neural specificity (CogniStemTM) have significant positive efficacy on chemotherapy-induced hearing loss and chemotherapy-induced neuropathic pain.

“The results show the potential wide usages of tissue specific/relevant mesenchymal stem cells from amniotic fluid as treatment in connection with cancer therapy and represent further validation of Amniotics platform and our therapeutic approach. We’re excited about the data presented and will now evaluate how to leverage on these findings,” says Jan Talts, COO at Amniotics.

Amniotics is a biopharmaceutical company focusing on mesenchymal stem cells (MSCs) from amniotic fluid. The company was born out of the discovery of a new source of stem cells in full-fledged amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Center and Skåne University Hospital in Lund, the company is a pioneer in harvesting and propagating tissue-specific mesenchymal stem cells of neonatal quality (MSC). Amniotics is now entering clinical trials with the leading drug candidate, PulmoStem, and wants to establish strategic partnerships with researchers and companies interested in developing stem cell-based therapies focused on diseases with highly fulfilled needs.

Disclaimer: HC Andersen Capital receives payment from Amniotics for a Digital IR / Corporate Visibility agreement